Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
KALA

Kala Pharmaceuticals

$18.56

-0.61 (-3.18%)

08:16
11/17/17
11/17
08:16
11/17/17
08:16
Recommendations
Kala Pharmaceuticals analyst commentary at JPMorgan »

Kala offers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a week ago
KALA

Kala Pharmaceuticals

$19.19

0.78 (4.24%)

08:02
11/13/17
11/13
08:02
11/13/17
08:02
Hot Stocks
Kala Pharmaceuticals names Todd Bazemore as COO »

Kala Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

KALA

Kala Pharmaceuticals

$19.19

0.78 (4.24%)

04:55
11/13/17
11/13
04:55
11/13/17
04:55
Conference/Events
Kala Pharmaceuticals management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

KALA

Kala Pharmaceuticals

$18.41

0.38 (2.11%)

09:24
11/10/17
11/10
09:24
11/10/17
09:24
Conference/Events
Kala Pharmaceuticals management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

KALA

Kala Pharmaceuticals

$16.50

-0.35 (-2.08%)

12:03
10/25/17
10/25
12:03
10/25/17
12:03
Recommendations
Kala Pharmaceuticals analyst commentary at Wells Fargo »

Kala new drug application…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALA

Kala Pharmaceuticals

$16.50

-0.35 (-2.08%)

08:09
10/25/17
10/25
08:09
10/25/17
08:09
Hot Stocks
Kala Pharmaceuticals files NDA with FDA for INVELTYSTM »

Kala Pharmaceuticals …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALA

Kala Pharmaceuticals

$16.50

-0.35 (-2.08%)

, AGN

Allergan

$182.92

-4.85 (-2.58%)

05:26
10/25/17
10/25
05:26
10/25/17
05:26
Recommendations
Kala Pharmaceuticals, Allergan analyst commentary at JPMorgan »

Kala Pharmaceuticals…

KALA

Kala Pharmaceuticals

$16.50

-0.35 (-2.08%)

AGN

Allergan

$182.92

-4.85 (-2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 28

    Oct

  • 01

    Nov

  • 06

    Nov

Over a month ago
KALA

Kala Pharmaceuticals

$22.84

-0.24 (-1.04%)

, ARLZ

Aralez

$2.29

0.12 (5.53%)

08:03
10/02/17
10/02
08:03
10/02/17
08:03
Hot Stocks
Kala Pharmaceuticals names Aralez president and CBO Andrew Koven to board »

Kala Pharmaceuticals…

KALA

Kala Pharmaceuticals

$22.84

-0.24 (-1.04%)

ARLZ

Aralez

$2.29

0.12 (5.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Over a quarter ago
BHF

Brighthouse Financial

$57.97

-0.53 (-0.91%)

, KALA

Kala Pharmaceuticals

$19.66

0.61 (3.20%)

10:43
08/14/17
08/14
10:43
08/14/17
10:43
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…

BHF

Brighthouse Financial

$57.97

-0.53 (-0.91%)

KALA

Kala Pharmaceuticals

$19.66

0.61 (3.20%)

BDSI

BioDelivery Sciences

CLXT

Calyxt

$11.82

-0.32 (-2.64%)

TRTX

TPG RE Finance

$19.82

-0.03 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

KALA

Kala Pharmaceuticals

$19.60

0.55 (2.89%)

09:12
08/14/17
08/14
09:12
08/14/17
09:12
Initiation
Kala Pharmaceuticals initiated at BofA/Merrill »

Kala Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.